Giancarlo Troncone

List of Publications by Year
in descending order

220	4,661	101496	168321
papers	citations	36 h-index	53 g-index

220	220	220	4876
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. British Journal of Cancer, 2017, 116, 802-810.	2.9	124
2	Rapid On-Site Evaluation of Endobronchial Ultrasoundâ€“Guided Transbronchial Needle Aspirations for the Diagnosis of Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2018, 142, 253-262.	1.2	116
3	Fine-needle aspiration biopsies of breast masses. A critical analysis of 1956 cases in 8 years (1976â€“1984). Cancer, 1988, 61, 2273-2277.	2.0	104
4	The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. Cancer Treatment Reviews, 2020, 85, 101994.	3.4	89
5	Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients. Translational Lung Cancer Research, 2016, 5, 505-510.	1.3	88
6	Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. Journal of Clinical Pathology, 2015, 68, 64-68.	1.0	81
7	Challenges and opportunities of nextâ€generation sequencing: a cytopathologist's perspective. Cytopathology, 2015, 26, 271-283.	0.4	76
8	Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy). PLoS ONE, 2013, 8, e83607.	1.1	76
9	Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. Journal of Clinical Pathology, 2016, 69, 767-771.	1.0	75
10	Liquid Biopsy and Lung Cancer. Acta Cytologica, 2019, 63, 489-496.	0.7	75
11	The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials. ESMO Open, 2021, 6, 100124.	2.0	75
12	EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in nonâ€“small cell lung carcinoma patients. Cancer Cytopathology, 2013, 121, 552-560.	1.4	71
13	Fine needle aspiration cytology and flow cytometry immunophenotyping of nonâ€Hodgkin lymphoma: can we do better?. Cytopathology, 2010, 21, 300-310.	0.4	70
14	How to prepare cytological samples for molecular testing. Journal of Clinical Pathology, 2017, 70, 819-826.	1.0	70
15	Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions. Molecular Oncology, 2019, 13, 2633-2645.	2.1	69
16	The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOMâ€“SIAPEC-IAPâ€“SIBioCâ€“SICâ€“SIF Italian Scientific Societies. ESMO Open, 2021, 6, 100164.	2.0	69
17	EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study. Journal of Clinical Pathology, 2012, 65, 87-91.	1.0	67
18	Consistency and reproducibility of nextâ€generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer Cytopathology, 2017, 125, 615-626.	1.4	58

#	Article	IF	Citations
19	Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Scientific Reports, 2017, 7, 9388.	1.6	56
20	Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7â€gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy. Cancer Cytopathology, 2020, 128, 107-118.	1.4	55
21	Cytologyâ€based gene mutation tests to predict response to antiâ€epidermal growth factor receptor therapy: A review. Diagnostic Cytopathology, 2011, 39, 703-710.	0.5	54
22	Potential involvement of neutrophils in human thyroid cancer. PLoS ONE, 2018, 13, e0199740.	1.1	54
23	USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs. Lung Cancer, 2017, 107, 41-49.	0.9	51
24	Cytopathologists can reliably perform ultrasoundâ€guided thyroid fine needle aspiration: a 1â€year audit on 3715 consecutive cases. Cytopathology, 2016, 27, 115-121.	0.4	50
25	Analysis of Differential miRNA Expression in Primary Tumor and Stroma of Colorectal Cancer Patients. BioMed Research International, 2014, 2014, 1-8.	0.9	49
26	Cytology in the time of coronavirus disease (COVID-19): an Italian perspective. Journal of Clinical Pathology, 2021, 74, 261-263.	1.0	49
27	KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting. Journal of Thoracic Disease, 2020, 12, 3836-3843.	0.6	47
28	Global impact of the COVIDâ€19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries. Cancer Cytopathology, 2020, 128, 885-894.	1.4	47
29	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. Translational Lung Cancer Research, 2017, 6, 373-386.	1.3	45
30	EGFR mutation detection on lung cancer cytological specimens by the novel fully automated PCR-based Idylla EGFR Mutation Assay. Journal of Clinical Pathology, 2017, 70, 295-300.	1.0	44
31	ALK and ROS1 testing on lung cancer cytologic samples: Perspectives. Cancer Cytopathology, 2017, 125, 817-830.	1.4	44
32	Liquid Biopsy in Prostate Cancer Managementâ€"Current Challenges and Future Perspectives. Cancers, 2022, 14, 3272.	1.7	44
33	Fine-needle aspiration biopsies of breast masses. An additional experience with 1153 cases (1985 to 1988) and a meta-analysis. Cancer, 1992, 69, 736-740.	2.0	42
34	An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. Expert Review of Molecular Diagnostics, 2018, 18, 35-45.	1.5	42
35	The Treatment of Advanced Melanoma: Therapeutic Update. International Journal of Molecular Sciences, 2022, 23, 6388.	1.8	41
36	Applications and limitations of oncogene mutation testing in clinical cytopathology. Seminars in Diagnostic Pathology, 2013, 30, 284-297.	1.0	40

#	Article	IF	Citations
37	Paclitaxel and Tacrolimus Coencapsulated Polymeric Micelles That Enhance the Therapeutic Effect of Drug-Resistant Ovarian Cancer. ACS Applied Materials & Interfaces, 2016, 8, 4368-4377.	4.0	39
38	Cell free DNA analysis by SiReÂ® next generation sequencing panel in non small cell lung cancer patients: focus on basal setting. Journal of Thoracic Disease, 2017, 9, S1383-S1390.	0.6	39
39	Consistency and reproducibility of nextâ€generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. Cancer Cytopathology, 2019, 127, 285-296.	1.4	39
40	Next generation sequencing in cytology. Cytopathology, 2021, 32, 588-595.	0.4	39
41	Epidermal Growth Factor Receptor Test Performed on Liquid-Based Cytology Lung Samples: Experience of an Academic Referral Center. Acta Cytologica, 2014, 58, 589-594.	0.7	37
42	Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples. Journal of Clinical Pathology, 2019, 72, 38-45.	1.0	37
43	EGFR analysis: Current evidence and future directions. Diagnostic Cytopathology, 2014, 42, 984-992.	0.5	36
44	A review on the Idylla platform: towards the assessment of actionable genomic alterations in one day. Journal of Clinical Pathology, 2018, 71, 757-762.	1.0	36
45	Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. Pathologica, 2020, 112, 248-259.	1.3	35
46	Tumor mutational burden on cytological samples: A pilot study. Cancer Cytopathology, 2021, 129, 460-467.	1.4	34
47	EGFR mutations detection on liquid-based cytology: is microscopy still necessary?. Journal of Clinical Pathology, 2012, 65, 561-564.	1.0	33
48	Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations. Cancer Cytopathology, 2018, 126, 317-325.	1.4	33
49	Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm. Journal of Clinical Pathology, 2018, 71, 745-750.	1.0	32
50	Understanding EGFR heterogeneity in lung cancer. ESMO Open, 2020, 5, e000919.	2.0	32
51	Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting. Cells, 2021, 10, 1878.	1.8	32
52	Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study. Critical Reviews in Oncology/Hematology, 2022, 169, 103525.	2.0	32
53	Impairment of T cell development and acute inflammatory response in HIV-1 Tat transgenic mice. Scientific Reports, 2015, 5, 13864.	1.6	31
54	Invited reviewâ€"next-generation sequencing: a modern tool in cytopathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 3-11.	1.4	31

#	Article	IF	Citations
55	Outsourcing cytological samples to a referral laboratory for <scp>EGFR</scp> testing in nonâ€small cell lung cancer: does theory meet practice?. Cytopathology, 2015, 26, 312-317.	0.4	30
56	Cytological preparations for molecular analysis: A review of technical procedures, advantages and limitations for referring samples for testing. Cytopathology, 2018, 29, 125-132.	0.4	30
57	EGFR T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing. Translational Lung Cancer Research, 2019, 8, 584-592.	1.3	30
58	KRAS inhibition in nonâ€“small cell lung cancer: Past failures, new findings and upcoming challenges. European Journal of Cancer, 2020, 137, 57-68.	1.3	30
59	Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study. Cells, 2020, 9, 2019.	1.8	30
60	Thyroid cytology smear slides: An untapped resource for ThyroSeq testing. Cancer Cytopathology, 2021, 129, 33-42.	1.4	30
61	Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. Journal of Thoracic Oncology, 2018, 13, 810-820.	0.5	29
62	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. European Journal of Cancer, 2021, 146, 74-83.	1.3	29
63	Fully automated PCR detection of KRAS mutations on pancreatic endoscopic ultrasound fine-needle aspirates. Journal of Clinical Pathology, 2016, 69, 986-991.	1.0	28
64	PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy. Pathology Research and Practice, 2021, 226, 153605.	1.0	28
65	PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory. Journal of Clinical Pathology, 2019, 72, 412-417.	1.0	26
66	Next Generation Sequencing in Cytopathology: Focus on Non-Small Cell Lung Cancer. Frontiers in Medicine, 2021, 8, 633923.	1.2	26
67	Evidenceâ€based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology. Cancer Cytopathology, 2022, 130, 96-109.	1.4	26
68	Spindle epithelial tumor with thymus-like differentiation (SETTLE): clinical-pathological features, differential pathological diagnosis and therapy. Endocrine, 2016, 51, 402-412.	1.1	24
69	Approach to cytological indeterminate thyroid nodules. Gland Surgery, 2019, 8, S98-S104.	0.5	24
70	Challenges facing pathologists evaluating PDâ€L1 in head & neck squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2021, 50, 864-873.	1.4	24
71	Lung adenocarcinoma and its thyroid metastasis characterized on fineâ€needle aspirates by cytomorphology, immunocytochemistry, and nextâ€generation sequencing. Diagnostic Cytopathology, 2015, 43, 585-589.	0.5	23
72	Improving anti-melanoma effect of curcumin by biodegradable nanoparticles. Oncotarget, 2017, 8, 108624-108642.	0.8	23

#	Article	IF	Citations
73	BRAF: A Two-Faced Janus. Cells, 2020, 9, 2549.	1.8	23
74	Hodgkin's disease mimicking suppurative lymphadenitis: A possible pitfall in fine-needle aspiration biopsy cytology. Diagnostic Cytopathology, 1989, 5, 282-285.	0.5	22
75	EGFR mutation detection on routine cytological smears of non-small cell lung cancer by digital PCR: a validation study. Journal of Clinical Pathology, 2016, 69, 454-457.	1.0	22
76	The reproducibility of PD-L1 scoring in lung cancer: can the pathologists do better?. Translational Lung Cancer Research, 2017, 6, S74-S77.	1.3	22
77	The continuing role of breast fineâ€needle aspiration biopsy after the introduction of the IAC Yokohama System For Reporting Breast Fine Needle Aspiration Biopsy Cytopathology. Diagnostic Cytopathology, 2020, 48, 1244-1253.	0.5	22
78	Digital Slides as an Effective Tool for Programmed Death Ligand 1 Combined Positive Score Assessment and Training: Lessons Learned from the â€œProgrammed Death Ligand 1 Key Learning Program in Head-and-Neck Squamous Cell Carcinomaâ€• Journal of Pathology Informatics, 2021, 12, 1.	0.8	22
79	UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients. Molecular Carcinogenesis, 2016, 55, 793-807.	1.3	21
80	Young investigator challenge: Can the Ion AmpliSeq Cancer Hotspot Panel v2 be used for nextâ€generation sequencing of thyroid FNA samples?. Cancer Cytopathology, 2016, 124, 776-784.	1.4	21
81	Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2. Oncotarget, 2015, 6, 4286-4298.	0.8	21
82	Immunohistochemical expression of mdm2 and p21WAF1 in invasive cervical cancer: correlation with p53 protein and high risk HPV infection. Journal of Clinical Pathology, 1998, 51, 754-760.	1.0	20
83	Cyclin dependent kinase inhibitor p27Kip1 expression in normal and neoplastic cervical epithelium. Journal of Clinical Pathology, 1999, 52, 880-887.	1.0	20
84	Cyclin-dependent kinase inhibitor p27Kip1 expression in thyroid cells obtained by fine-needle aspiration biopsy: A preliminary report. Diagnostic Cytopathology, 2000, 23, 77-81.	0.5	20
85	KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. Oncotarget, 2018, 9, 26279-26290.	0.8	20
86	Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. Expert Review of Molecular Diagnostics, 2021, 21, 1165-1178.	1.5	20
87	Molecular status ofPI3KCA,KRASandBRAFin ovarian clear cell carcinoma: an analysis of 63 patients. Journal of Clinical Pathology, 2016, 69, 1088-1092.	1.0	19
88	c-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer. Diagnostic Cytopathology, 1996, 14, 135-139.	0.5	18
89	BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients. Critical Reviews in Oncology/Hematology, 2020, 156, 103118.	2.0	17
90	Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe. Journal of Clinical Pathology, 2021, 74, 391-395.	1.0	17

#	Article	IF	Citations
91	RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer. Cancers, 2021, 13, 139.	1.7	17
92	Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. American Journal of Physiology - Renal Physiology, 2014, 306, F1243-F1250.	1.3	16
93	There is still a role for cytology in the â€˜liquid biopsyâ€™ era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression. Journal of Clinical Pathology, 2017, 70, 798-802.	1.0	16
94	Rapid Onâ€site Molecular Evaluation in thyroid cytopathology: A sameâ€day cytological and molecular diagnosis. Diagnostic Cytopathology, 2020, 48, 300-307.	0.5	16
95	Current Prognostic and Predictive Biomarkers for Endometrial Cancer in Clinical Practice: Recommendations/Proposal from the Italian Study Group. Frontiers in Oncology, 2022, 12, 805613.	1.3	16
96	A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. Cancers, 2019, 11, 147.	1.7	15
97	Cytopathology practice during the COVIDâ€19 postlockdown: An Italian experience. Cancer Cytopathology, 2021, 129, 548-554.	1.4	15
98	A Novel Approach to Classification and Reporting of Lymph Node Fine-Needle Cytology: Application of the Proposed Sydney System. Diagnostics, 2021, 11, 1314.	1.3	15
99	Diagnostic mesothelioma biomarkers in effusion cytology. Cancer Cytopathology, 2021, 129, 506-516.	1.4	15
100	EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature review. Translational Cancer Research, 2018, 8, S64-S69.	0.4	15
101	COVIDâ€19 pandemic impact on cytopathology practice in the postâ€lockdown period: An international, multicenter study. Cancer Cytopathology, 2022, 130, 344-351.	1.4	15
102	Is the Idylla EGFR Mutation Assay feasible on archival stained cytological smears? A pilot study. Journal of Clinical Pathology, 2019, 72, 609-614.	1.0	14
103	Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution. Endocrine, 2021, 73, 358-366.	1.1	14
104	Osteomyelitis byParacoccidioides brasiliensis (South American blastomycosis): Cytologic diagnosis on fine-needle aspiration biopsy smears: A case report. , 1996, 15, 442-446.		13
105	KRAS Mutant Allele-Specific Imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer. Journal of Clinical Pathology, 2015, 68, 265-269.	1.0	13
106	Multiplex digital colour-coded barcode technology on RNA extracted from routine cytological samples of patients with non-small cell lung cancer: pilot study. Journal of Clinical Pathology, 2017, 70, 803-806.	1.0	13
107	miR-29b inhibits non-small cell lung cancer progression by targeting STRN4. Human Cell, 2020, 33, 220-231.	1.2	13
108	Mesonephric-like adenocarcinoma of the ovary. Medicine (United States), 2020, 99, e23450.	0.4	13

#	Article	IF	Citations
109	Predictive molecular pathology in the time of COVID-19. Journal of Clinical Pathology, 2021, 74, 234-237.	1.0	13
110	Cellular pathology in the COVID-19 era: a European perspective on maintaining quality and safety. Journal of Clinical Pathology, 2021, 74, 64-66.	1.0	13
111	Thyroid fine-needle aspiration trends before, during, and after the lockdown: what we have learned so far from the COVID-19 pandemic. Endocrine, 2021, 71, 20-25.	1.1	13
112	Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future. ESMO Open, 2021, 6, 100024.	2.0	13
113	Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network. Pathologica, 2021, 113, 262-271.	1.3	13
114	Mesonephric adenocarcinomas in female genital tract. Medicine (United States), 2021, 100, e27174.	0.4	13
115	Impact of mobile devices on cancer diagnosis in cytology. Diagnostic Cytopathology, 2022, 50, 34-45.	0.5	13
116	C-Erbb-2 Expression and Dna Ploidy Status In Breast Cancer Cells Obtained By Fine Needle Aspiration (Fna). Cytopathology, 1993, 4, 195-205.	0.4	12
117	EGFR mutation detection by microfluidic technology: a validation study. Journal of Clinical Pathology, 2013, 66, 982-984.	1.0	12
118	Thyroid FNA in the time of coronavirus: The interventional cytopathologist point of view. Cancer Cytopathology, 2020, 128, 589-589.	1.4	12
119	Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer. Frontiers in Oncology, 2020, 10, 560.	1.3	12
120	Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record. Cancers, 2020, 12, 1800.	1.7	12
121	KRAS testing on coloâ€rectal carcinoma cytological imprints. Diagnostic Cytopathology, 2011, 39, 274-277.	0.5	11
122	Microsatellite instability evaluation by automated microfluidic electrophoresis: an update. Journal of Clinical Pathology, 2017, 70, 90.2-91.	1.0	11
123	Harmonization of Next-Generation Sequencing Procedure in Italian Laboratories: A Multi-Institutional Evaluation of the SiReÂ® Panel. Frontiers in Oncology, 2020, 10, 236.	1.3	11
124	Thyroid cytology in the times of coronavirus. Diagnostic Cytopathology, 2021, 49, 467-468.	0.5	11
125	Pathologists and the coronavirus distraction effect. Journal of Clinical Pathology, 2021, 74, 205-206.	1.0	11
126	Comprehensive genomic profiling of combined small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 636-650.	1.3	11

#	Article	IF	Citations
127	PDâ€Ł1 and beyond: Immunoâ€oncology in cytopathology. Cytopathology, 2021, 32, 596-603.	0.4	11
128	A rapid near-patient RT-PCR test for suspected COVID-19: a study of the diagnostic accuracy. Annals of Translational Medicine, 2021, 9, 921-921.	0.7	11
129	Predictive markers in lung cancer: a few hints for the practicing pathologist. Pathologica, 2018, 110, 29-38.	1.3	11
130	The Cause of Death of a Child in the 18th Century Solved by Bone Microbiome Typing Using Laser Microdissection and Next Generation Sequencing. International Journal of Molecular Sciences, 2017, 18, 109.	1.8	10
131	Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study. Diagnostics, 2022, 12, 477.	1.3	10
132	bel-2 protein in breast cancer cells obtained by fine needle aspiration (FNA): a preliminary report. Cytopathology, 1995, 6, 219-225.	0.4	9
133	Evaluation of KRAS, NRAS and BRAF mutational status and microsatellite instability in early colorectal carcinomas invading the submucosa (pT1): towards an in-house molecular prognostication for pathologists?. Journal of Clinical Pathology, 2020, 73, 741-747.	1.0	9
134	<scp>PDâ€Ł1</scp> expression in cellâ€blocks of nonâ€small cell lung cancer: The impact of prolonged fixation. Diagnostic Cytopathology, 2020, 48, 595-603.	0.5	9
135	The Two Sides of Cytopathology during the COVID-19 Health Emergency: Screening versus Diagnosis. Pathobiology, 2021, 88, 106-107.	1.9	9
136	Reference standards for gene fusion molecular assays on cytological samples: an international validation study. Journal of Clinical Pathology, 2023, 76, 47-52.	1.0	9
137	Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment. Histology and Histopathology, 2020, 35, 741-749.	0.5	9
138	KRAS detection on archival cytological smears by the novel fully automated polymerase chain reaction-based Idylla mutation test. CytoJournal, 2017, 14, 5.	0.8	9
139	Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study.. Journal of Clinical Oncology, 2022, 40, 3503-3503.	0.8	9
140	Intraâ€institutional second opinion diagnosis can reduce unnecessary surgery for indeterminate thyroid <scp>FNA</scp>: A preliminary report on 34 cases. Cytopathology, 2017, 28, 254-258.	0.4	8
141	<i>BRAF</i> Mutations in Lung Cancer. Acta Cytologica, 2019, 63, 247-250.	0.7	8
142	Liquid biopsy for BRAF mutations testing in non-small cell lung cancer: a retrospective study. Journal of Clinical Pathology, 2020, , jclinpath-2020-207107.	1.0	8
143	Juggling the COVIDâ€19 pandemic: A cytopathology point of view. Cytopathology, 2021, 32, 299-303.	0.4	8
144	Next-generation sequencing in the genomic profiling of synchronous colonic carcinomas: comment on Liet al(2015). Journal of Clinical Pathology, 2015, 68, 946-947.	1.0	7

#	Article	IF	Citations
145	Evaluation of a novel liquid biopsy-based ColoScape assay for mutational analysis of colorectal neoplasia and triage of FIT+ patients: a pilot study. Journal of Clinical Pathology, 2018, 71, 1123-1126.	1.0	7
146	Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984642.	1.4	7
147	Predictive biomarkers for molecular pathology in lung cancer. Biomarkers in Medicine, 2020, 14, 253-257.	0.6	7
148	Circulating tumor DNA in cancer: Predictive molecular pathology meets mathematics. Critical Reviews in Oncology/Hematology, 2021, 163, 103394.	2.0	7
149	Retrospective evaluation of DNA ploidy of hepatocarcinoma on cytologic samples. Diagnostic Cytopathology, 1998, 19, 323-329.	0.5	6
150	EGFR mutant allelic-specific imbalance assessment in routine samples of non-small cell lung cancer. Journal of Clinical Pathology, 2015, 68, 739-741.	1.0	6
151	Allâ€inâ€one: The dream and reality of molecular cytopathology testing on routine lung cancer smears. Cancer Cytopathology, 2018, 126, 155-157.	1.4	6
152	Atypical carcinoid of the uterine cervix accompanying adenocarcinoma in situ. Journal of Clinical Pathology, 2018, 71, 1030-1030.	1.0	6
153	Moving towards a local testing solution for undetermined thyroid fine-needle aspirates: validation of a novel custom DNA-based NGS panel. Journal of Clinical Pathology, 2022, 75, 465-471.	1.0	6
154	Performance evaluation of a fully closed real-time PCR platform for the detection of KRAS p.G12C mutations in liquid biopsy of patients with non-small cell lung cancer. Journal of Clinical Pathology, 2022, 75, 350-353.	1.0	6
155	Evaluation of a fully closed real time PCR platform for the detection of SARS-CoV-2 in nasopharyngeal swabs: a pilot study. Journal of Clinical Pathology, 2022, 75, 551-554.	1.0	6
156	Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. Critical Reviews in Oncology/Hematology, 2021, 160, 103300.	2.0	6
157	Liquid Biopsy Analysis in Clinical Practice: Focus on Lung Cancer. Journal of Molecular Pathology, 2021, 2, 241-254.	0.5	6
158	TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study. Journal of Clinical Pathology, 2022, 75, 416-421.	1.0	6
159	Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients. Critical Reviews in Oncology/Hematology, 2022, 169, 103536.	2.0	6
160	Application of the Milan System for Reporting Salivary Gland Cytopathology in pediatric patients: An international, multiâ€institutional study. Cancer Cytopathology, 2022, 130, 370-380.	1.4	6
161	Circulating Tumour Cells in Predictive Molecular Pathology: Focus on Drug-Sensitive Assays and 3D Culture. Acta Cytologica, 2019, 63, 171-181.	0.7	5
162	Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 15, 231-242.	1.7	5

#	Article	IF	Citations
163	How the COVID-19 Pandemic Impacted Oncological Molecular Diagnosis: A Picture from a National Reference Center for Molecular Pathology. BioMed Research International, 2020, 2020, 1-7.	0.9	5
164	Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 87-96.	1.5	5
165	MMR profile and microsatellite instability status in colorectal mucinous adenocarcinoma with synchronous metastasis: a new clue for the clinical practice. Journal of Clinical Pathology, 2023, 76, 492-496.	1.0	5
166	Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report. Current Oncology, 2021, 28, 5401-5407.	0.9	5
167	Morphological and immunocytochemical features of Merkel cell carcinoma metastatic to the pancreas diagnosed by endoscopic ultrasoundâ€guided fineâ€needle aspiration. Diagnostic Cytopathology, 2017, 45, 629-630.	0.5	4
168	Role of Cytomorphology in the Era of Liquid Biopsy. Acta Cytologica, 2019, 63, 497-505.	0.7	4
169	Multi-gene custom panels for the characterisation of metastatic colorectal carcinoma in clinical practice: express the role ofPIK3CAmutations. Journal of Clinical Pathology, 2022, 75, 488-492.	1.0	4
170	The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. Expert Review of Molecular Diagnostics, 2021, 21, 757-766.	1.5	4
171	Methods for actionable gene fusion detection in lung cancer: now and in the future. Pharmacogenomics, 2021, 22, 833-847.	0.6	4
172	Generation and Characterization of a Tumor Stromal Microenvironment and Analysis of Its Interplay with Breast Cancer Cells: An In Vitro Model to Study Breast Cancer-Associated Fibroblast Inactivation. International Journal of Molecular Sciences, 2022, 23, 6875.	1.8	4
173	UbcH10 overexpression is less pronounced in older colorectal cancer patients. International Journal of Colorectal Disease, 2016, 31, 1367-1368.	1.0	3
174	Malpâ€2, an agonist of tlr6, promotes the immune status without affecting the differentiation capacity of umbilical cord mesenchymal stem cells. Experimental and Therapeutic Medicine, 2017, 14, 5540-5546.	0.8	3
175	Birdâ€™s eye view of modern cytopathology: Report from the seventh international Molecular Cytopathology Meeting in Naples, Italy, 2018. Cancer Cytopathology, 2019, 127, 350-357.	1.4	3
176	Microfluidic chip technology applied to fineâ€needle aspiration cytology samples for IGH clonality assessment. Diagnostic Cytopathology, 2019, 47, 749-757.	0.5	3
177	Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network. Journal of Clinical Pathology, 2020, 74, jclinpath-2020-206800.	1.0	3
178	Biomarkers predictive value in early stage non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 956-959.	1.3	3
179	A narrative review of lung cancer cytology in the times of coronavirus: what physicians should know. Translational Lung Cancer Research, 2020, 9, 2074-2081.	1.3	3
180	Cytology meets next generation sequencing and liquid biopsy: A case of lung adenocarcinoma presenting as metastasis to the phalanx. Diagnostic Cytopathology, 2020, 48, 759-764.	0.5	3

#	Article	IF	Citations
181	Digital Slide Assessment for Programmed Death-Ligand 1 Combined Positive Score in Head and Neck Squamous Carcinoma: Focus on Validation and Vision. Frontiers in Artificial Intelligence, 2021, 4, 684034.	2.0	3
182	Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice. Journal of Clinical Pathology, 2021, , jclinpath-2020-207339.	1.0	3
183	Cytopathology meets basic science. Cancer Cytopathology, 2015, 123, 571-572.	1.4	2
184	Discordance in RAS Mutations between Primary Colon Tumor and Metastases: A Real Event or a Matter of Methodology?. International Journal of Biological Markers, 2017, 32, 474-477.	0.7	2
185	The cytopathologist's expanding role in the 2018 updated molecular testing guidelines for lung cancer. Cancer Cytopathology, 2018, 126, 753-755.	1.4	2
186	Molecular predictive testing in precision oncology: The Italian experience. Cancer Cytopathology, 2020, 128, 622-628.	1.4	2
187	Nonâ€human papilloma virus associated adenocarcinomas of the cervix uteri. Cytologic features and diagnostic agreement using whole slide digital cytology imaging. Diagnostic Cytopathology, 2021, 49, 316-321.	0.5	2
188	Primary dedifferentiated Liposarcoma of vagina: a first case report. Diagnostic Pathology, 2021, 16, 3.	0.9	2
189	Cytopathology Practice in the COVID-19 Era: Focus on Sample Workload. Journal of Molecular Pathology, 2021, 2, 109-113.	0.5	2
190	Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice. Annals of Translational Medicine, 2021, 9, 1027-1027.	0.7	2
191	Molecular Testing of Thyroid Fine-Needle Aspiration: Local Issues and Solutions. An Interventional Cytopathologist Perspective. Journal of Molecular Pathology, 2021, 2, 233-240.	0.5	2
192	Modern Cytopathology: An evolving field. Cytopathology, 2021, 32, 560-561.	0.4	2
193	Multifocality and Hashimotoâ€™s thyroiditis as independent predictors of structural recurrence in a cohort of low risk intrathyroidal papillary thyroid cancer.. Journal of Clinical Oncology, 2017, 35, e17577-e17577.	0.8	2
194	Ovarian endometrioid adenocarcinoma a with yolk sac tumor in a 41-year-old woman: a case report. International Journal of Clinical and Experimental Pathology, 2019, 12, 3549-3554.	0.5	2
195	BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report. Genes, 2021, 12, 1917.	1.0	2
196	Comparison of two next-generation sequencing-based approaches for liquid biopsy analysis in patients with non-small cell lung cancer: a multicentre study. Journal of Clinical Pathology, 2023, 76, 206-210.	1.0	2
197	RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center. Personalized Medicine, 2022, 19, 395-401.	0.8	2
198	How should a follicular adenoma with papillary architecture be classified on thyroid <scp>FNA</scp>? Case report with histological correlation. Cytopathology, 2015, 26, 256-258.	0.4	1

#	Article	IF	Citations
199	Letter to the Editor. Clinical Lung Cancer, 2018, 19, e149.	1.1	1
200	Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line FIr-B/FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome.. Journal of Clinical Oncology, 2017, 35, 644-644.	0.8	1
201	Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial. Translational Cancer Research, 2019, 8, S145-S148.	0.4	1
202	Differential clinical outcome of metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing.. Journal of Clinical Oncology, 2017, 35, e15041-e15041.	0.8	1
203	Analysis of Programmed Death-Ligand 1 Expression, Stromal Tumor-Infiltrating Lymphocytes, and Mismatch Repair Deficiency in Invasive Micropapillary Carcinoma of the Breast. Journal of Immunotherapy and Precision Oncology, 2019, 2, 130-136.	0.6	1
204	Inhibition of cervical cancer cells by co-culturing with mesenchymal stem cells. International Journal of Clinical and Experimental Pathology, 2018, 11, 2506-2513.	0.5	1
205	Tissue Microarray from Cell Block Material (cbTMA)â€"An Additional Shot for Cytology in the Predictive Pathology Era: The PD-L1 Experience. Journal of Molecular Pathology, 2022, 3, 15-23.	0.5	1
206	Predictive molecular pathology in metastatic thyroid cancer: the role of RET fusions. Expert Review of Endocrinology and Metabolism, 2022, 17, 167-178.	1.2	1
207	<scp>MicroRNA</scp> profiling predicts positive nodal status in papillary thyroid carcinoma in the preoperative setting. Cancer Cytopathology, 2022, , .	1.4	1
208	Microsatellite instability evaluation of patients with solid tumour: routine practice insight from a large series of Italian referral centre. Journal of Clinical Pathology, 2022, , jclinpath-2022-208203.	1.0	1
209	Fineâ€needle aspiration findings in focal (nodular) myositis of a newborn: A case report. Diagnostic Cytopathology, 2015, 43, 920-923.	0.5	0
210	Reply to Costs of ALK, ROS1, EGFR, and KRAS testing in nonâ€"small cell lung cancer: About different strategies in France. Cancer Cytopathology, 2017, 125, 877-877.	1.4	0
211	Integrated screening methodologies for patients harboring colo rectal cancer into the TAIEX context. European Journal of Public Health, 2017, 27, .	0.1	0
212	RNA-Based Assays. , 2019, , 99-119.		0
213	The Birth of the Journal of Molecular Pathology. Journal of Molecular Pathology, 2020, 1, 1-2.	0.5	0
214	Comparison between two different next generation sequencing platforms for clinical relevant gene mutation test in solid tumours. Journal of Clinical Pathology, 2020, 73, 602-604.	1.0	0
215	EGFR mutation detection on lung cancer cytological specimens by the rapid and fully integrated Idylla molecular diagnostics system.. Journal of Clinical Oncology, 2016, 34, e20542-e20542.	0.8	0
216	Fully automated PCR detection of KRAS mutations on pancreatic endoscopic ultrasound fine needle aspirates.. Journal of Clinical Oncology, 2016, 34, e15726-e15726.	0.8	0

#	Article	IF	Citations
217	Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.. Journal of Clinical Oncology, 2018, 36, e15517-e15517.	0.8	0
218	A liquid biopsy model to detect eventual pollutants as â€œone healthâ€•tool. European Journal of Public Health, 2021, 31, .	0.1	0
219	Clinicopathologic correlates and prognostic relevance of the immune checkpoint CD73 (NT5E) in resected biliary cancers (BC).. Journal of Clinical Oncology, 2022, 40, 473-473.	0.8	0
220	Fine-Needle Aspiration Is Suitable for Breast Cancer BRCA Molecular Assessment: A Case Report. Journal of Molecular Pathology, 2021, 2, 319-324.	0.5	0